{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-328747","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.117714+00:00","generated_at":"2026-05-16T12:25:34.502075+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total","bullets":["Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.","Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.","Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.","Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.","Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-328747","json":"https://secwatch.observer/filing/0001193125-25-328747.json","markdown":"https://secwatch.observer/filing/0001193125-25-328747.md","text":"https://secwatch.observer/filing/0001193125-25-328747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/0001193125-25-328747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000119312525328747/flgt-20251220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:25:34.502075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}